Introduction
For the 33 million people infected with HIV-1, highly active antiretroviral therapy (HAART) is currently the only treatment that can stop disease progression. HAART consists of selected combinations of three different antiretroviral drugs [1 ] . In the majority of patients who take the drugs correctly, HAART is successful in reducing the level of viremia to below 50 copies of HIV-1 RNA per milliliter of plasma, the limit of detection of clinical assays [2] [3] [4] . Despite optimistic early predictions [4] , HAART does not cure HIV-1 infection, due in part to persistence of a population of resting memory CD4 þ T cells that harbor quiescent viral genomes and that are capable of producing infectious virus upon cellular activation [5] [6] [7] . Nevertheless, in patients who maintain levels of viremia below 50 copies/ml, disease progression is halted and partially reversed. Although these patients do have trace levels of viremia, which is detectable with special assays [8, 9] , a recent study demonstrated that addition of a fourth antiretroviral drug to their regimens does not further reduce this residual viremia [10 ] . The implication is that residual viremia originates from stable reservoirs rather than ongoing cycles of replication. Thus, current HAART regimens appear to have largely reached their theoretical potential of halting ongoing viral replication.
Despite the success of HAART, a clear understanding of the quantitative aspects of antiviral drug activity is still lacking. In particular, it is still not clear how in-vitro measures of antiviral drug activity relate to the performance of the drugs in patients. Antiviral activity is typically expressed in terms of the IC 50 , the concentration of drug that inhibits viral replication by 50%, or the inhibitory quotient (IQ), the ratio of the plasma drug concentration Purpose of review With highly active antiretroviral therapy, HIV-1 infection has become a manageable lifelong disease. Developing optimal treatment regimens requires understanding how to best measure anti-HIV activity in vitro and how drug dose-response curves generated in vitro correlate with in-vivo efficacy.
Recent findings
Several recent studies have indicated that conventional multiround infectivity assays are inferior to single cycle assays at both low and high levels of inhibition. Multiround infectivity assays can fail to detect subtle but clinically significant anti-HIV activity. The discoveries of the anti-HIV activity of the hepatitis B drug entecavir and the herpes simplex drug acyclovir were facilitated by single-round infectivity assays. Recent studies using a single-round infectivity assay have shown that a previously neglected parameter, the dose-response curve slope, is an extremely important determinant of antiviral activity. Some antiretroviral drugs have steep slopes that result in extraordinary levels of antiviral activity. The instantaneous inhibitory potential, the log reduction in infectivity in a single-round assay at clinical drug concentrations, has been proposed as a novel index for comparing antiviral activity. Summary Among in-vitro measures of antiviral activity, single-round infection assays have the advantage of measuring instantaneous inhibition by a drug. Re-evaluating the antiviral activity of approved HIV-1 drugs has shown that the slope parameter is an important factor in drug activity. Determining the instantaneous inhibitory potential by using a single-round infectivity assay may provide important insights that can predict the in-vivo efficacy of anti-HIV-1 drugs.
(D) achieved during standard dosing to the IC 50 . Recent research has highlighted problems with the conventional approaches for the in-vitro analysis of anti-HIV activity. For example, it has been shown that conventional assays can miss subtle but clinically significant anti-HIV activity of drugs used to treat other viral infections. In addition, it has become clear that standard measures like IC 50 and IQ are inadequate because they fail to consider the doseresponse curve slope, which is an extremely important determinant of the inherent inhibitory potential of antiviral drugs. As a result, these measures do not accurately predict the drug classes with the greatest in-vivo efficacy. In this review, we discuss the ways in which antiviral activity has been traditionally measured and consider new approaches for measuring and describing anti-HIV activity that more accurately capture the in-vivo activity of antiretroviral drugs.
In-vitro assays for antiretroviral drugs
The in-vitro assessment of anti-HIV activity is typically accomplished by measuring infection in the presence of increasing concentrations of drug in conventional multiround assays or newer single-round assays. A summary of the major features of multiround and single-round assays is presented in Table 1 .
Multiround assays
In multiround assays, cell lines or mitogen-activated peripheral blood mononuclear cells (PBMCs) isolated from healthy individuals are infected with replicationcompetent, cell-free virus and cultured for a period of several days to weeks [11] [12] [13] . Quantification of viral antigen (p24) or reverse transcriptase activity in culture supernatants is used to determine the amount of virus produced. Some multiround infection assays use cell viability as a readout [14] . Viral cytopathic effects on host cells can be quantified using a soluble tetrazolium reagent that is metabolically reduced to a colored formazan product in viable cells. Although these measurements can easily be made by common colorimetric techniques, this assay is indirect. Regardless of the readout used, multiround assays are time-consuming and not always reproducible between laboratories [15] .
A more significant problem with multiround assays was pointed out by Ferguson et al. [16] . They noted that multiround assays measure cumulative outcomes of infection after drug has been added rather than instantaneous inhibition by the drug. Factors such as target cell proliferation or death, virus decay, and viral cytopathic effects can influence the outcome. Their modeling suggested that IC 50 values and the steepness of doseresponse curves could vary depending on endpoint chosen [16] , making it difficult to compare results from different studies. Thus, multiround assays may over or underestimate a drug effect. The fundamental problem with such assays is that the outcome depends on multiple factors in addition to the intrinsic antiviral activity of the drug being tested. As pointed out by Ferguson et al. [16] , any drug that reduces the basic reproductive ratio (R 0 , the number of newly infected cells arising from virus produced by a single infected cell) to less than 1 can cause the infection to extinguish. Thus, multiround assays may not distinguish drugs that cause an immediate halt to all infectious cycles from drugs that merely reduce R 0 to a value below 1. In cases in which cell lines are used, there is an additional problem that the outcome may be affected by cell-specific factors not representative of the CD4 þ T lymphoblasts, which are the primary target cells for HIV-1 in vivo.
Depending on the length of the assay, multiround infection assays may have the added complication of the production of viral variants during sequential rounds of replication. Although a culture may begin with a clonal virus population, each new round of infection will generate variants that may have altered susceptibility to the drug being tested. In some cases, one point mutation in the viral genome may confer high-level resistance to a drug. For example, the K103N and M184V mutations in reverse transcriptase dramatically decrease virus susceptibility to the nonnucleoside reverse transcriptase inhibitor (NNRTI) efavirenz and the nucleoside reverse transcriptase inhibitor (NRTI) lamivudine, respectively [17] [18] [19] [20] . Thus, dose-response curves may not reflect a true drug effect if there is evolution of resistant variants.
Multiround infection assays have been used to compare the fitness of viral variants in a single culture. An excellent summary of these methods has recently been published by Dykes and Demeter [21] . Typically, two viral variants are mixed at a known ratio and used to infect cells in the presence or absence of drug. After several weeks in culture, the relative percentage of each variant can be measured using various assays, including clonal analysis or flow cytometry as described by Martinez-Picado and Martinez [22 ] . Although informative, these types of assays generally take up to several weeks to complete, are labor-intensive, and the data interpretation is still controversial.
Single-round infectivity assays
A more rapid alternative to multiround infection assays are single-round infectivity assays exemplified by the commercial systems used to measure HIV-1 drug resistance [15, 23, 24] . One such assay [23] relies on production of virus particles in the readily transfectable human embryonic kidney (HEK) cell line 293T and infection of the same cell line. Two plasmids are cotransfected into HEK 293T cells: one containing the HIV-1 genome with part of the envelope gene deleted and replaced with a luciferase reporter gene and the second plasmid containing the murine leukemia virus (MLV) envelope gene. Culture supernatants containing pseudovirions are collected and used to infect a new culture of HEK 293T cells in the presence of increasing drug concentrations. Patient-derived partial pol sequences can be incorporated into the parent HIV-1 vector to test patient virus susceptibility to individual antiretroviral drugs. Typically, uncloned patient sequences amplified from plasma are used. Phenotypic analysis is especially useful for patients who are HAART-experienced and who have complicated genotypes. Dose-response curves of pseudovirus populations containing patient-derived pol sequences are generated and the IC 50 values obtained are compared to those of wild-type virus under the same conditions.
An alternative single-round phenotypic assay [24,25 ,26] replaces the luciferase indicator gene with the enhanced green fluorescent protein (GFP) gene and uses the HIV-1 CXCR4 or CCR5 tropic envelope instead of MLV envelope ( Fig. 1a ). Production of virus is done similarly in HEK 293T cells, but infection is done in primary CD4 þ T cells, the main target cells of HIV-1 in vivo, rather than transformed cell lines. Infecting primary CD4 þ T cells has the advantage of allowing measurement of drug inhibition by HIV-1 entry inhibitors such as enfuvirtide, whereas cell lines such as HEK 293T must be transfected with the CD4 and the CXCR4 or CCR5 coreceptor genes to allow HIV-1 envelope-mediated entry. Because infectivity is measured by flow cytometric quantitation of the number of GFP-expressing cells, this assay has the sensitivity to detect individual infection events and a wide dynamic range ( Fig. 1a) , with the main limitation being the number of cells infected. Because of the wide dynamic range, measurements of drug inhibition at clinically relevant concentrations can be made for some drugs. The single-round phenotypic assay can be performed in a high-throughput fashion using 96-well plates (Fig. 1a ), making it a useful tool for drug screening.
The most significant advantage of the single-round infectivity assays is that it measures instantaneous inhibition by the drug rather than cumulative effects in long-term culture. Because of the defective envelope gene in the HIV-1 vectors used, the pseudovirus particles generated in such assays are capable of only a single round of infection. As is discussed below, the degree to which the drug inhibits this single-round infection is a simple and accurate reflection of the intrinsic antiviral activity of the drug. Several recent studies have highlighted the advantages of this approach in measuring anti-HIV activity.
Anti-HIV activity of entecavir and acyclovir
The single-round phenotypic assay was able to detect the potent but partial inhibition of HIV-1 replication by the hepatitis B drug entecavir [26] . Entecavir is a deoxyguanosine analogue that can be incorporated by hepatitis B virus polymerase, leading to chain termination [28] . Interestingly, initial studies with a multiround assay in cell lines did not detect any effect of this drug on HIV-1 replication [28] . However, a single-round assay detected anti-HIV activity at concentrations as low as 1 nmol/l and confirmed the entecavir resistance of the M184V reverse transcriptase mutant ( Fig. 1b) identified in an HIVhepatitis B-coinfected patient taking entecavir monotherapy. In this study, an approximately 0.5 log 10 decline in HIV-1 RNA was seen in three coinfected patients taking entecavir, though only one of the three patients selected the M184V mutant HIV-1 variant [26] . This result was confirmed independently in a fourth HIVhepatitis B-coinfected patient [29] and in a retrospective analysis of HAART-naive and HAART-experienced coinfected patients taking entecavir monotherapy [30 ] .
These observations were initially challenged by Soriano et al. [31] , who did not observe a decline in plasma HIV-1 RNA levels in an HIV-hepatitis delta virus-coinfected patient on entecavir. However, the M184V mutation was later identified in this patient after an extended duration of entecavir monotherapy [32 ] . Thus, it appears clear that entecavir can inhibit HIV-1 in vivo and select for the M184V mutation in HIV-1 reverse transcriptase, a mutation that also confers high-level resistance to the widely used HIV-1 drugs lamivudine and emtricitabine [17] [18] [19] . The use of entecavir monotherapy in coinfected patients is now contraindicated [30 ] .
In addition to these clinical and functional studies, direct inhibition of HIV-1 reverse transcriptase by entecavir triphosphate has been demonstrated at the biochemical level [33 ,34 ] in support of the single-round phenotypic assay data. Interestingly, using single-round infectivity assays with a luciferase reporter, Lin et al. [35 ] found that the sensitivity of HIV-1 to inhibition by entecavir was dependent on the multiplicity of infection (MOI). In this study, lower MOIs gave lower IC 50 values, though entecavir was generally not as potent as observed in the GFP reporter assay [26] . It is likely that low MOI assays more closely mimic in-vivo infection. In addition, when measuring the instantaneous inhibition of viral replication by nucleoside analogues, it is important to allow time for the drug to become activated to its triphosphate form.
In the entecavir studies done with the GFP reporter system [26] , the cells were preincubated with drug for 16-20 h prior to infection. This has been shown to be the optimal time for activation of the NRTIs [24] . Thus, in the study by Lin et al., the potency of entecavir may be underestimated as the drug was added at the time of infection or shortly after in some cases.
Another interesting recent example of the usefulness of single-round assays is the discovery of the anti-HIV activity of acyclovir, a nucleoside analogue used to treat herpes simplex virus (HSV) infection. In HSV-infected cells, phosphorylation of acyclovir by HSV thymidine kinase allows the generation of the active triphosphate form of the drug, which is a substrate for HSV DNA polymerase, resulting in chain termination. Using a single-round infectivity assay with a GFP-expressing HIV-1 pseudovirus, McMahon et al. [27 ] screened a clinical compound library containing over 3000 drugs and drug-like molecules [36] (Fig. 1b) . Surprisingly, acyclovir showed significant anti-HIV activity in CD4 þ T cells from normal donors. In addition, the single-round assay confirmed the acyclovir resistance of the V75I variant in HIV-1 reverse transcriptase that was selected for in vitro using a multiround infection assay [27 ] . The anti-HIV activity of acyclovir was also identified by Lisco et al. [37 ] using a replication-competent virus in a human tonsil 
In-vitro measures of antiviral activity
Regardless of which in-vitro assay is used, the classic method to analyze antiviral drug effects is to obtain dose-response curves by plotting the fraction of infection events unaffected by the drug ( f u ) vs. the log of the drug concentration ( Fig. 2a ). The IC 50 , which can be readily determined from such plots, is widely used to compare the potency of individual drugs. However, plasma concentrations of antiretroviral drugs achieved with standard dosing are typically well above the IC 50 . Thus, IQ, the ratio of plasma drug concentration (D) to the IC 50 , has been introduced as a second measure of drug activity. IQ takes into account two important dimensions of antiviral activity and appears to be a predictor of virological responses in patients on some protease inhibitor-based regimens [41 ] . However, all widely applicable theoretical models for drug activity, including the sigmoidal E max model and the medianeffect model, state that drug activity depends on three parameters: D, IC 50 , and a third parameter, the doseresponse curve slope (m) [42] . A recent study has shown that this third parameter is a critical determinant of the inhibitory activity of antiviral drugs [25 ] . The importance of the slope parameter is revealed in a dramatic fashion when the traditional semi-log dose-response curves ( f u vs. log D) are transformed to log-log plots (log f u vs. log D). On the traditional semi-log plots, drugs with different values of the slope parameter appear to be equally efficient at inhibiting replication at clinically relevant drug concentrations ( Fig. 2a ). However, transformation of these plots into log-log plots reveals that the dose-response curve slope dramatically affects the level of inhibition that can be achieved at clinically relevant drug concentrations (Fig. 2b) . Using a linear scale for inhibition obscures the difference between modest inhibition (99%) and very high level inhibition (99.9999%). Because viruses replicate exponentially, the inhibition of viral replication is best considered on a logarithmic scale. When this is done, the importance of the slope parameter as a determinant of antiviral activity becomes immediately obvious.
The slope parameter is analogous to the Hill coefficient [43] , a measure of cooperativity in the binding of multiple ligand molecules to a multivalent receptor. Because there is only a single binding site for NRTIs, NNRTIs, and protease inhibitors on the relevant HIV-1 enzymes, the slope parameter has largely been ignored in the analysis of anti-HIV drugs. In fact, prior to the study by Shen et al. [25 ] , the values of the slope parameter had not been measured for antiretroviral drugs using an appropriate methodology. As mentioned above, the slope parameter cannot be accurately obtained using multiround assays. Shen et al. [25 ] used a single-round assay with a pseudovirus carrying the gene for GFP to measure the slope parameter for antiretroviral drugs in current use. This assay detects individual infection events and has the sensitivity and dynamic range necessary for accurate measurement of m. Interestingly, they discovered that slope values are different for different classes of antire-troviral drugs and seem to correlate with the mechanism of drug action. The NRTIs and integrase inhibitors have slopes of approximately 1, whereas the NNRTIs, protease inhibitors, and entry inhibitors have slopes more than 1. Thus, the slope parameter has to be considered for accurate evaluation of antiviral activity.
To incorporate all three dimensions affecting antiviral activity -IC 50 , D, and m -into one single measure of antiviral activity, a new index termed instantaneous inhibitory potential (IIP) was developed [25 ] . IIP is the number of the logs by which single-round infectivity is reduced at clinically relevant drug concentrations and can be calculated based on the median-effect model (Fig. 2b) . The biological meaning of IIP can also be understood from an experimental perspective. Consider an experiment in which 10 6 infected (GFP þ ) cells are detected by flow cytometry in the absence of drug in the single-round infectivity assay described above (Fig. 1a ).
In the presence of a drug with an IIP value of 2, a 2 log reduction can be achieved but 10 4 infection events will still be observed. However, in the presence of a drug with an IIP value more than 6, such as the NNRTI efavirenz and some protease inhibitors, it may be difficult to detect even a single infected cell (Fig. 2c) . A typical in-vivo concentration range 10-100-fold above the IC 50 is indicated in the shaded area. Antiviral activity for drugs with different m values appears similar at C max in this kind of plot. (b) A log-log plot of the same curves revealing the dramatic impact of slope on the inhibitory potential of antiretroviral drugs. Instantaneous inhibitory potential (IIP) is the number of logs of reduction of single-round infectivity at a clinically relevant drug concentration. At C max , a drug with a slope of 3 can achieve 6 logs of inhibition (IIP ¼ 6), which is 10 000-fold greater than that of a drug with a slope of 1. This dramatic influence of slope on antiviral activity is only evident in the log-log plot because the difference between 2 logs (99%) and 6 logs (99.9999%) of inhibition is small in a linear-log plot. The equation for calculation of IIP is also shown. (c) Hypothetical flow cytometry plots for infections in the presence and absence of antiviral drugs. Expression of green fluorescent protein (GFP) is an indicator of successful infection. In this example, 10 6 GFP þ cells are detected in cultures without antiviral drugs. In cultures treated with an antiviral drug with IIP ¼ 2, 10 4 infection events are still readily detectable at D ¼ C max . However, in the presence of a drug with IIP ¼ 6, only one GFP þ cell on average may be detected at D ¼ C max .
Notably, IIP is strongly dependent upon the slope parameter and varies by more than 8 logs for currently available anti-HIV drugs. The NRTIs and integrase inhibitors can only produce 1-3.5 logs of inhibition of single-round replication, largely because of the intrinsic limitation on antiviral activity imposed by their low slope values. Some NNRTIs and protease inhibitors, however, have high slope values and can achieve IIP values of 5-10. The extraordinary ability of these drugs to inhibit viral replication is apparent when using IIP as a measure for antiviral activity, but is not evident if IC 50 or IQ values are used for comparison. Interestingly, the drugs that can maintain IIP more than 5 for 24 h after the last dose, including the NNRTI efavirenz and boosted forms of the protease inhibitors darunavir and atazanavir, have not been beaten in head-to-head comparative clinical trials and are recommended as the mainstays of initial HAART regimens [1 ]. Therefore, IIP may provide a valuable new tool for evaluating antiviral activity more accurately in vitro. The high inhibitory potential of certain antiretroviral drugs also helps to explain the results of HAART intensification studies, which suggest that current regimens stop ongoing replication [10 ] .
In-vivo measures of antiviral activity
As antiretroviral drugs must generally be used in combinations of three or more to achieve optimal suppression of HIV-1 replication [1 ], it is much more difficult to evaluate the relative efficacy of individual drugs in vivo. Because monotherapy can result in the rapid emergence of resistance [44] [45] [46] , clinical trials involving monotherapy can only be carried out under certain situations and over a short period of time. In cases in which monotherapy data are available, the rate of decay of viremia and the magnitude of the drop in viremia have both been used to assess the in-vivo antiviral activity of new drugs [47] . The initial rate of decay of viremia has also been used as a measure of the antiviral activity of combination therapy regimens [48] . One important question is whether newer in-vitro measures of antiviral activity such as IIP can be directly related to the initial decay rate of viremia or the magnitude of the drop in viremia. Interest in this issue has been heightened by a study [49] showing that the rate of decay of viremia is faster in patients initiating therapy with regimens containing the integrase inhibitor raltegravir than in patients initiating standard efavirenz-based regimens. However, a recent modeling study has shown that the rate of decay of viremia is influenced by where in the life cycle an antiretroviral drug acts [50 ] . Drugs that act later in the viral life cycle (such as integrase inhibitors) will produce a more rapid decay in viremia as the observed decay reflects the turnover of cells that are still capable of producing virus in the presence of the drugs. The rapid decay in viremia in the presence of integrase inhibitors reflects the fact that only cells past the integ-ration step are capable of producing virus. In contrast, in patients on efavirenz-based regimens, all cells past the reverse transcription step can produce virus. This is a larger population of cells and hence the decay in viremia is slower. This simple concept may explain why a very rapid drop in viremia has been observed with raltegravir in a 10-day monotherapy study [51] and as part of a HAART regimen for naive patients [49] . Thus, the rapid decay of viremia in patients on raltegravir is not necessarily indicative of unique efficacy. Rather, it is an expected consequence of the fact that raltegravir acts later in the virus life cycle compared with NNRTIs and protease inhibitors. Furthermore, the magnitude of the drop in viremia caused by a single agent is also influenced by the rate at which resistance develops [46] . Therefore, more complex models are needed to correlate in-vivo parameters, such as the rate and extent of the decay of viremia, with drug efficacy.
Conclusion
Although antiviral activity can be measured by many different ways using multiround or single-round infectivity assays, a standardized approach is desirable for comparing the efficacy of currently approved drugs and novel drugs. Sensitive single-round infectivity assays offer the best approach for detecting anti-HIV activity at both ends of the inhibition spectrum. Differences in the level of inhibition at clinically relevant drug concentrations cannot be appreciated with traditional log-linear doseresponse curves. When the slope parameter is considered and the dose-response curves are plotted on a logarithmic scale, it becomes evident that some antiretroviral drugs have an extraordinarily high potential to inhibit viral replication in vivo. An understanding of why certain drug classes, like the protease inhibitors, can inhibit viral replication by as much as 6-10 logs may provide new insight into designing novel inhibitors and provide a rationale for choosing HAART regimens.
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